

Special Issue

HIV and Drug of Abuse

Message from the Guest Editors

Due to the lack of a vaccine against HIV, precautions and anti-HIV therapies are the only available solutions. It is now well documented that drugs of abuse, in addition to deteriorating the central nervous system (CNS) function, accelerate the natural course of HIV disease progression. Significant progress has been made in uncovering the underlying molecular mechanism that different drugs of abuse influence to modulate HIV gene expression, transmission, and associated disease progression. Nevertheless, the effects of drug abuse on HIV are multifaceted and largely unclear, and further investigations are required in order to understand the in-depth molecular mechanisms and how they can be used for therapeutic benefits. Studies to understand these mechanisms may reveal new drug targets and open up new avenues for better pharmaceutical interventions in HIV-infected drug abusers.

Guest Editors

Dr. Mudit Tyagi

Center for Translational Medicine, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA

Dr. Adhikarimayum Lakhikumar Sharma

Centre for Translational Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA

Deadline for manuscript submissions

closed (30 April 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/89254

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).